A Pilot Study to Assess the Preliminary Efficacy of EDTA Eye Drops on Band Keratopathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03985371|
Recruitment Status : Not yet recruiting
First Posted : June 13, 2019
Last Update Posted : August 13, 2019
|Condition or disease||Intervention/treatment||Phase|
|Corneal Dystrophy, Band-Shaped||Drug: EDTA Eye Drops||Early Phase 1|
This study is an open-label, pilot study of up to 6 subjects with documented BK.
This study has 2 phases: In Phase 1 subjects must be willing to return to the clinic for evaluation of safety and BK symptoms during the treatment period of 6 months (Days 7, 60, 120, 180) and for follow up at Months 9 and 12. In Phase 2 subjects must be willing to return to the clinic at 18 and 24 months post-first dose for a final evaluation.
On Day 1 of the study, potential subjects will be screened and if they meet entry requirements they will be enrolled in the study.
Once enrolled, subjects will be assessed for baseline symptoms and visual acuity, have corneal photographs taken of their affected eye, dispensed EED and instructed to use it for 2 times/day for 6 months in the eye with BK. They will be dosed for the first time in the clinic in order to show them how to consistently use the drops. Subjects will also be given a diary card to record potential adverse events and pain levels (with the first level being noted in the clinic), dismissed from the clinic and reminded to return on Day 7 for assessment of tolerability and safety.
At each subsequent visit (Days 7, 60, 120, 180) the subject will be asked to rate their pain at the time of the visit on a pain analog scale. Their diary card will be reviewed for potential adverse events (AEs) and use of EED will be assessed for technique and compliance. Between visits, subjects will be called every 4 weeks by a member of the study site team to assess potential AEs and dosing compliance.
Additionally, the subject or their caregiver will check the treated eye on a weekly basis and note whether the calcific bands are still present on the diary card. When bands have disappeared, subject will notify the eye clinic and schedule a return visit to obtain corneal photographs and visual acuity test. This may occur outside the planned study visits.
On Day 180, subjects will present at the clinic to return their diary card and unused study product. They will be asked to return to the clinic on Days 270 and 360 for assessment of their visual acuity, pain, corneal photography of the affected eye and potential AEs.
Day 360 will be considered the end of study phase 1. Phase 2 of the study includes long term follow up for possible recurrence. Subjects will be scheduled to return for follow-up visits at months 18 and 24 for assessment of visual acuity and recurrence of BK symptoms.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Pilot Study to Assess the Safety, Tolerability and Preliminary Efficacy of EDTA Eye Drops on Band Keratopathy|
|Estimated Study Start Date :||September 2019|
|Estimated Primary Completion Date :||September 2020|
|Estimated Study Completion Date :||September 2021|
|Experimental: Drops Used||
Drug: EDTA Eye Drops
One drop in the Band Keratopathy affected eye only, two times per day for six months.
- Changes of the Cornea [ Time Frame: Days 1, 120 and 180 after the start of the study. ]Photographs will be full, direct views taken with a Zeiss model 450 plus split lamp camera.
- Change in Snellen Visual Acuity [ Time Frame: Days 1, 7, 60, 120 and 180 after the start of the study. ]The Snellen Chart is used to assess visual acuity by asking subjects to read as many of the 11 lines of block letters as they are able.
- Change in the Symptoms Associated with Band Keratopathy [ Time Frame: Days 1, 7, 60, 180, 270, 360, 540 and 720 after the start of the study. ]Evaluation of pain, as rated by the subject on a visual analog scale, will be the primary symptom assessed throughout this study.